MTA-cooperated PRMT5 inhibitors can specifically target MTAP deficient tumor cells without affecting normal cells, indicating that the precise targeting function of antibody-drug conjugate (ADC) has been achieved through small molecules, which is a breakthrough in the development of anti-tumor small molecule drugs. Here, PRMT5 is linked to neoplasm.